BioSight
Therapeutics for Oncology and Hematological Disorders
Company Overview
Snapshot
Founded in November 1999 by Stela Gengrinovitch and Mark Gengrinovitch, BioSight operates with 1–10 employees. The company raised a total of $62.5M across 5 funding rounds from 9 investors. In October 2023, BioSight was acquired by Ayala Pharmaceuticals.
Business overview
BioSight is a clinical-stage biotechnology company focused on developing therapeutics for hematological malignancies and disorders. Its core product, BST-236 (aspacytarabine), is a proprietary anti-metabolite designed to enable high-dose therapy with reduced systemic toxicity. The company serves the oncology and hematology markets, operating within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.
Strategic signal
In November 2022, BioSight initiated a Phase 1/2 clinical trial for Aspacytarabine in combination with Venetoclax for first-line AML induction therapy, followed by Aspacytarabine consolidation. This development signals the company's continued commitment to advancing its lead product and expanding its potential applications in acute myeloid leukemia treatment, indicating a strategic focus on clinical validation and market expansion prior to its acquisition.
Log in to access full profile ›Company Intelligence Q&A
- What was BioSight's most significant corporate event?
- In October 2023, BioSight was acquired by Ayala Pharmaceuticals, marking a significant exit for the company and its investors.
- What is BioSight's primary therapeutic focus?
- BioSight is primarily focused on developing therapeutics for hematological malignancies and disorders, with its lead product BST-236 targeting acute myeloid leukemia (AML).
- Did BioSight receive any special regulatory designations for its lead product?
- In August 2020, BioSight was granted U.S. FDA Fast Track Designation for BST-236 for the treatment of Acute Myeloid Leukemia, following an Orphan Drug Designation from the FDA in June 2019 for the same indication.
- What was a key clinical development for BioSight in 2022?
- In November 2022, BioSight launched a Phase 1/2 clinical trial of Aspacytarabine in combination with Venetoclax for first-line AML induction therapy, followed by Aspacytarabine consolidation.